Autologous Cellular Immunotherapy Treatment is covered only when the beneficiaries'(suffering from asymptomatic or minimally symptomatic hormone refractory prostate cancer) health outcome can be improved.

https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=344&ncdver=1&bc=AAAAgAAAAAAA&
